You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
|
|---|---|
| Published in |
Journal for Immunotherapy of Cancer, June 2015
|
| DOI | 10.1186/s40425-015-0070-4 |
| Pubmed ID | |
| Authors |
Michael A. Postow, Manuarii Manuel, Phillip Wong, Jianda Yuan, Zhiwan Dong, Cailian Liu, Solène Perez, Isabelle Tanneau, Marlène Noel, Anaïs Courtier, Nicolas Pasqual, Jedd D. Wolchok |
| Abstract |
Ipilimumab improves overall survival in a subset of patients with metastatic melanoma. Peripheral blood T cell receptor (TCR) repertoire diversity has been associated with favorable outcomes in patients with cancer, but its relevance as a biomarker for ipilimumab outcomes remains unknown. In this pilot study, we analyzed the pre-treatment peripheral blood TCR repertoire in 12 patients with metastatic melanoma who received ipilimumab at 3 mg/kg (clinical benefit, n = 4; no clinical benefit, n = 8). TCR diversity was evaluated using a polymerase chain reaction assay which measures TCR combinatorial diversity between V and J genes from genomic DNA. TCR repertoire diversity was studied through richness (observed V-J rearrangements) and evenness (similarity between the frequencies of specific V-J rearrangements). The Wilcoxon rank sum test was used to compare patients with clinical benefit and those without. Association with benefit in a dichotomized analysis was assessed through a Fisher's exact test. Overall survival was studied through log-rank analysis. There was a significant difference in richness (p = 0.033) and evenness (p = 0.028) between patients with and without clinical benefit. Dichotomized analysis showed that none of the patients with low richness (n = 0/5, p = 0.081) nor low evenness (n = 0/7, p = 0.01) achieved clinical benefit. There were no significant differences in overall survival. In this small group of patients, baseline TCR diversity in the peripheral blood was associated with clinical outcomes. Further investigation is ongoing in larger cohorts of patients to explore these preliminary findings and determine whether TCR diversity can be used as a predictive biomarker in cancer immunotherapy. |
X Demographics
The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 3 | 33% |
| Canada | 2 | 22% |
| Unknown | 4 | 44% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 5 | 56% |
| Scientists | 3 | 33% |
| Practitioners (doctors, other healthcare professionals) | 1 | 11% |
Mendeley readers
The data shown below were compiled from readership statistics for 159 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| United States | 1 | <1% |
| France | 1 | <1% |
| Unknown | 156 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 31 | 19% |
| Student > Ph. D. Student | 29 | 18% |
| Student > Master | 16 | 10% |
| Other | 10 | 6% |
| Student > Doctoral Student | 10 | 6% |
| Other | 26 | 16% |
| Unknown | 37 | 23% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 40 | 25% |
| Biochemistry, Genetics and Molecular Biology | 30 | 19% |
| Agricultural and Biological Sciences | 21 | 13% |
| Immunology and Microbiology | 13 | 8% |
| Computer Science | 3 | 2% |
| Other | 9 | 6% |
| Unknown | 43 | 27% |
Attention Score in Context
This research output has an Altmetric Attention Score of 34. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 April 2023.
All research outputs
#1,195,724
of 25,959,914 outputs
Outputs from Journal for Immunotherapy of Cancer
#284
of 3,485 outputs
Outputs of similar age
#13,543
of 266,771 outputs
Outputs of similar age from Journal for Immunotherapy of Cancer
#2
of 16 outputs
Altmetric has tracked 25,959,914 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,485 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 15.6. This one has done particularly well, scoring higher than 91% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 266,771 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 94% of its contemporaries.
We're also able to compare this research output to 16 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 87% of its contemporaries.